Erdheim-Chester disease: Characteristics and management

Mayo Clinic Proceedings

Volumn 89, Issue 7, 2014, Pages 985-996

  Munoz, Javier ^a   Janku, Filip ^b   Cohen, Philip R ^c   Kurzrock, Razelle ^c  

^a Banner MD Anderson Cancer Center   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CORTICOSTEROID; ETOPOSIDE; IMATINIB; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; VEMURAFENIB; VINBLASTINE;

ANTIGEN PRESENTING CELL; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIABETES INSIPIDUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TOLERABILITY; ERDHEIM CHESTER DISEASE; FATIGUE; HUMAN; LANGERHANS CELL HISTIOCYTOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW;

ALGORITHMS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DECISION SUPPORT TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; ERDHEIM-CHESTER DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS;

EID: 84904766986     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.01.023     Document Type: Review

References (85)

1. Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factorsin Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778-2782.
2. Marchal A, Cuny JF, Montagne K, Haroche J, Barbaud A, Schmutz JL. Associated Langerhans cell histiocytosis and Erdheim-Chester disease [in French]. Ann Dermatol Venereol. 2011;138(11):743-747.
3. Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbationof cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 2011;117(10):2783-2790.
4. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012; 120(13):2700-2703.
5. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9): 1495-1500.
6. Adam Z, Koukalová R, Sprláková A, et al. Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review [in Czeck]. Vnitr Lek. 2011;57(6):576-589.
7. Esmaeli B, Ahmadi A, Tang R, Schiffman J, Kurzrock R. Interferon therapy for orbital infiltration secondary to Erdheim- Chester disease. Am J Ophthalmol. 2001;132(6):945-947.
8. Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106(9):2992-2994.
9. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010;28(31):e633-e636.
10. Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116(20):4070- 4076.
11. Tran TA, Pariente D, Lecron JC, Delwail A, Taoufik Y, Meinzer U. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. Arthritis Rheum. 2011; 63(12):4031-4032.
12. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol. 2012;24(1):53-59.
13. Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer. 1999;35(5):747-767; discussion 767-769.
14. Jolles S. Paul Langerhans. J Clin Pathol. 2002;55(4):243.
15. Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med. 2000;342(26): 1969-1978.
16. Windebank K. Advances in the management of histiocytic disorders. Paediatr Child Health. 2008;18(3):129-135.
17. Offret H, Hannouche D, Frau E, Doyon D, Quillard J, Schaison G. Orbital Erdheim-Chester disease. J Francais D'Ophtalmologie. 1995;18(3):220-225.
18. Breuil V, Brocq O, Pellegrino C, Grimaud A, Euller-Ziegler L. Erdheim-Chester disease: typical radiological bone features for a rare xanthogranulomatosis. Ann Rheum Dis. 2002;61(3): 199-200.
19. Kenn W, EckM, Allolio B, et al. Erdheim-Chester disease: evidence for a disease entity different from Langerhans cell histiocytosis? Three cases with detailed radiological and immunohistochemical analysis. Hum Pathol. 2000;31(6):734-739.
20. Egan AJ, Boardman LA, Tazelaar HD, et al. Erdheim-Chester disease: clinical, radiologic, and histopathologic findings in fivepatients with interstitial lung disease. Am J Surg Pathol. 1999; 23(1):17-26.
21. Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore). 2004;83(6):371-392.
22. Haroche J, Amoura Z, Wechsler B, Veyssier-Belot C, Charlotte F, Piette JC. Erdheim-Chester disease [French]. La Presse Médicale. 2007;36(11, Pt 2):1663-1668.
23. Sedrak P, Ketonen L, Hou P, et al. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR. Am J Neuroradiol. 2011;32(11):2126-2131.
24. Shamburek RD, Brewer HB Jr, Gochuico BR. Erdheim-Chester disease: a rare multisystem histiocytic disorder associated with interstitial lung disease. Am J Med Sci. 2001;321(1):66-75.
25. Arnaud L, Pierre I, Beigelman-Aubry C, et al. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum. 2010;62(11):3504-3512.
26. Dion E, Graef C, Miquel A, et al. Bone involvement in Erdheim- Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology. 2006;238(2):632-639.
27. Haroche J, Cluzel P, Toledano D, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation. 2009; 119(25):e597-e598.
28. Tsuji Y, Kogawa K, Imai K, Kanegane H, Fujimoto J, Nonoyama S. Evans syndrome in a patient with Langerhans cell histiocytosis: possible pathogenesis of autoimmunity in LCH. Int J Hematol. 2008;87(1):75-77.
29. Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor a as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 2012;30(28):e286-e290.
30. Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum. 2006;54(12):4018-4022.
31. Mossetti G, Rendina D, Numis FG, Somma P, Postiglione L, Nunziata V. Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin- 6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease. Clin Exp Rheumatol. 2003;21(2):232-236.
32. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11): 1919-1923.
33. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
34. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
35. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829): 1893-1901.
36. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):782-789.
37. Jakobson AM, Kreuger A, Hagberg H, Sundstrom C. Treatment of Langerhans cell histiocytosis with alpha-interferon. Lancet. 1987;2(8574):1520-1521.
38. Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim- Chester histiocytosis. Blood. 2008;111(11):5413-5415.
39. Srikulmontree T, Massey HD, Roberts WN. Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action. Rheumatol Int. 2007;27(3): 303-307.
40. Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Int Med. 2001;135(9):844-845.
41. Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med. 2012;157(2):94-103.
42. Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54(10):3330-3336.
43. Benz R, Siciliano RD, Stussi G, Fehr J. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol. 2009;82(3): 194-200.
44. Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. 1997;15(5): 1803-1810.
45. Seymour JF, Estey EH, Keating MJ, Kurzrock R. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia. 1995; 9(5):929-932.
46. Husken AC, Tsianakas A, Hensen P, et al. Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous Tcell lymphoma. J Eur Acad Dermatol Venereol. 2012;26(1):71-78.
47. Suzuki HI, Hosoya N, Miyagawa K, et al. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res. 2010;34(1):e21-e24.
48. Hervier B, Arnaud L, Charlotte F, et al. Treatment of Erdheim- Chester disease with long-term high-dose interferon-alpha. Semin Arthritis Rheum. 2012;41(6):907-913.
49. Utikal J, Ugurel S, Kurzen H, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol. 2007;143(6):736-740.
50. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344(14):1038-1042.
51. Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86(4):362-371.
52. Rutkowski P, Wozniak A, Switaj T. Advances in molecular characterizationand targeted therapy in dermatofibrosarcoma protuberans. Sarcoma. 2011;2011:959132.
53. Reichardt P, Reichardt A, Pink D. Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Targets. 2011; 11(6):688-697.
54. Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol. 2012;9(6):351-358.
55. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92(9):1173- 1179.
56. Koos B, Jeibmann A, Lünenbürger H, et al. The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors. Cancer. 2010;116(21): 5075-5081.
57. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010;116(18):3409-3417.
58. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110(8):2828-2837.
59. Cohen PR, Kurzrock R. Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. Dermatol Online J. 2014;20(1):21241.
60. Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim-Chester disease. Rheum Dis Clin North Am. 2013;39(2):299-311.
61. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6(4):232-241.
62. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer Suppl. 1994;23:S37-S40.
63. Geyer M, Muller-Ladner U. Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol. 2010; 22(3):246-251.
64. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.
65. Ostensen M, Förger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011; 23(3):293-298.
66. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28-e34.
67. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013;31(20):e351-e352.
68. Chen MT, Wang SM, Lin SY, et al. Pericardial effusion as a crucial presentation of Erdheim-Chester disease in a hemodialysis patient: an overlooked diagnosis. Clin Nephrol. 2012;78(1):81-84.
69. Taguchi T, Iwasaki Y, Asaba K, et al. Erdheim-Chester disease: report of a case with PCR-based analysis of the expression of osteopontin and survivin in Xanthogranulomas following glucocorticoid treatment. Endocr J. 2008;55(1):217-223.
70. Mahnel R, Tan KH, Fahlbusch R, et al. Problems in differential diagnosis of non Langerhans cell histiocytosis with pituitary involvement: case report and review of literature. Endocr Pathol. 2002;13(4):361-368.
71. Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111(5):2556-2562.
72. Broccoli A, Stefoni V, Faccioli L, et al. Bilateral orbital Erdheim- Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. Rheumatol Int. 2012;32(7):2209-2213.
73. Adam Z, Balsíková K, Pour L, et al. Diabetes insipidus followed, after 4 years, with dysarthria and mild right-sided hemiparesise the first clinical signs of Erdheim-Chester disease. Description and depiction of a case with a review of information on the disease [in Czeck]. Vnitr Lek. 2009;55(12):1173-1188.
74. Lachenal F, Cotton F, Desmurs-Clavel H, et al. Neurological manifestations and neuroradiological presentation of Erdheim- Chester disease: report of 6 cases and systematic review of the literature. J Neurol. 2006;253(10):1267-1277.
75. Adam Z, Balsíková K, Krejcí M, et al. Central diabetes insipidus in adult patientsethe first sign of Langerhans cell histiocytosis and Erdheim-Chester disease. Three case studies and literature review [in Czeck]. Vnitr Lek. 2010;56(2):138-148.
76. Adam Z, Sprláková A, Rehák Z, et al. Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide [in Czeck]. Klin Onkol. 2011;24(5):367-381.
77. Adam Z, Szturz P, Pour L, et al. Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group [in Czeck].Vnitr Lek. 2012;58(6):455-465.
78. Gaspar N, Boudou P, Haroche J, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica. 2006;91(8):1121-1125.
79. Ishii R, Morimoto A, Ikushima S, et al. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;47(2): 194-199.
80. Janku F, Munoz J, Subbiah V, Kurzrock R. A tale of two histiocytic disorders. Oncologist. 2013;18(1):2-4.
81. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011;6(9):1601-1612.
82. Munoz J, Kurzrock R. Targeted therapy in rare cancerseadopting the orphans. Nat Rev Clin Oncol. 2012;9(11):631-642.
83. Munoz J, Swanton C, Kurzrock R. Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book. 2013;33:127-134.
84. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther. 2007;6(4): 1175-1179.
85. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22): 6373-6383.